Integral Diagnostics Stock

Integral Diagnostics P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Integral Diagnostics (IDX.AX) as of Aug 3, 2026 is 63.83. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was 21.16 — a change of 201.73% (higher).

P/FCF

63.83

YoY

201.73%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Integral Diagnostics is 2026 63.83 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Integral Diagnostics was 2025 21.16 . It decreases by 201.73% higher compared to the previous year.
Access this data via the Eulerpool API

Integral Diagnostics Stock analysis

What does Integral Diagnostics do? Integral Diagnostics Ltd is an Australian company that has been providing medical imaging services for over 25 years. The company was founded in 1994 by Dr. Ian Kadish and a team of radiologists in Perth, Western Australia, offering radiology services to local clinics and hospitals. Over the years, Integral Diagnostics has expanded its services to provide imaging services nationwide. The business model of Integral Diagnostics is to deliver medical imaging to enable doctors and their patients to have a fast and accurate diagnosis. The company offers imaging services for a variety of medical specialties, including radiology, cardiology, obstetrics and gynecology, and neurology. They operate over 49 locations in Australia, many of which are in rural areas where access to medical care may be limited. Integral Diagnostics offers a wide range of products based on medical imaging. These include X-rays, mammography, ultrasound, CT scans, MRI scans, PET scans, and bone density scans. The company takes pride in being one of the few Australian medical imaging companies to offer a complete range of imaging services. Their services are conducted by qualified radiologists specialized in interpreting medical images. Integral Diagnostics also operates clinics for performing diagnostic and therapeutic procedures such as biopsies, drainages, and injections. These procedures are carried out by highly qualified radiologists to provide patients with faster and more accurate diagnoses. Integral Diagnostics is committed to quality assurance and has a comprehensive quality management system that is annually reviewed by independent auditors. The company is accredited by both the Australian Medical Association and the Australian National Accreditation Scheme (NATA). These accreditations recognize the high standards that Integral Diagnostics sets for delivering medical imaging services. One of Integral Diagnostics' recent activities is their use of artificial intelligence (AI) in image interpretation. The company has partnered with MaxQ AI, a leading provider of AI solutions for medical imaging. Through this partnership, Integral Diagnostics doctors can utilize the latest AI tools to improve their patients' diagnoses. Integral Diagnostics is a strong advocate for social justice and is dedicated to supporting disadvantaged communities in Australia. The company has partnered with nonprofit organizations such as the National Breast Cancer Foundation, The Smith Family, and the Friendship Foundation. Overall, Integral Diagnostics has undergone impressive growth over the past 25 years and is now a leading Australian medical imaging company. With a wide range of imaging services and a strong focus on quality and social responsibility, the company is well-positioned to continue its success in the future. Integral Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Integral Diagnostics stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Integral Diagnostics is 63.83 in 2026.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Integral Diagnostics changed from 21.16 to 63.83, representing a 201.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Integral Diagnostics since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Integral Diagnostics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Integral Diagnostics

All Key Metrics — Integral Diagnostics